The trajectory of the erectile dysfunction drug presents a challenging picture for shareholders. While the initial introduction generated massive profits, the expiration of its intellectual property protection opened https://1001bookmarks.com/story21494459/sildenafil-and-the-pharmaceutical-industry-a-risky-opportunity